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Department of Surgery, Geneva University Hospitalsﬁeld deserves further assessment. Similarly, ex situ machine per-
fusion, either normothermic, hypothermic or sub-normothermic
has conﬁrmed protective effects on liver ischemia/reperfusion
lesions, but its impact on cancer has never been tested [4–8].
The minimal required time of liver graft reperfusion for pre-
venting HCC growth is currently unknown. The used two-hour
reperfusion matches international reports with NECMO or ex situ
machine perfusion ranging between one and four hours [3,7,8]. It
is also in agreement with the need for a minimal two-hour graft
normothermic machine reperfusion in order to restore the
function of ischemic rat livers [4].
Overall, ischemia/reperfusion may be an added factor altering
post-transplant cancer recurrence. This link is likely weaker
than the one between pre-transplant HCC characteristics and
recurrence, but it deserves further exploration both to better
understand the underlying mechanisms and the ways to prevent it.Conﬂict of interest
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Transplant 2012;12:162–170.c antibodies in liver-transplant
ithout calcineurin inhibitorsTo the Editor:
After liver transplantation (LT), immunosuppression with mam-
malian target-of-rapamycin (mTOR) inhibitors without calcineu-
rin inhibitors (CNIs) is used to preserve kidney function [1], and
because of its anti-neoplastic effect, particularly for patients
who have a history of hepatocellular carcinoma [2]. However,
in kidney-transplant patients, this immunosuppressive strategy
has been associated with an increased risk of developing donor-
speciﬁc antibodies (DSAs) [3]. After a LT, although the impact of
the occurrence of de novo DSAs on short- and long-term out-
comes is still controversial [4], de novo DSAs are associated with
an increased risk of antibody-mediated rejection [5], chronic
rejection [6–8], and anastomotic biliary stricture [9]. However,
because the incidence of de novo DSAs using the Luminex assay
in liver-transplant patients receiving mTOR inhibitor-basedimmunosuppression is unknown, this was the aim of this retro-
spective study.
Between 2008 and 2013, 394 liver-transplant patients were
followed-up in our institution. Of these, 61 patients were receiv-
ing an mTOR inhibitor (6.5%). Five of the 61 patients were
excluded from the study: four because they had not undergone
anti-HLA screening after conversion to mTOR inhibitors, and
one patient because he received both CNIs and mTOR inhibitors.
Hence, 56 liver-transplant patients, converted from CNIs to mTOR
inhibitors, were included in this study (Table 1). Twelve patients
had undergone an abrupt conversion from CNIs to sirolimus and
44 patients had undergone progressive conversion to everolimus.
The target trough (C0) levels for sirolimus and everolimus were
6–10 ng/ml. The median time between conversion to mTOR
inhibitors and the last follow-up was 28 (range: 2–102) months.4 vol. 61 j 962–966 963
Anti-HLA antibodies were searched for in a Luminex single-
antigen assay (One Lambda, Canoga Park, CA) before the switch
to mTOR inhibitors and annually thereafter, plus each time the
patient presented with increased liver-enzyme levels. A baseline
value of mean ﬂuorescence intensity (MFI) >1000 was considered
positive.
Before conversion to mTOR inhibitors, 47 liver-transplant
patients had no anti-HLA antibodies. The median follow-up time
after the switch was 28 (range: 2–102) months. Three of these 47
patients developed de novo DSAs (6.5%). All patients were given
tacrolimus before conversion to mTOR inhibitors. One patient
presented with an anti-DQ3 antibody (MFI 5500) and the second
patient developed an anti-DR1 antibody (MFI 6000), respectively,
at 8 and 13 months after conversion. Both these patients were
receiving sirolimus (C0 = 10 ng/ml) and steroids (5 mg/d). When
the DSAs were detected, both patients presented concomitantly
with cholestasis and cytolysis. However, because both patients
had a severe relapse of hepatocellular carcinoma, no liver biopsy
was performed, the immunosuppressive therapy was not
modiﬁed, and both patients died a few months later. The third
patient was receiving everolimus (C0 = 7 ng/ml) and steroids
(5 mg/d), and developed an anti-DQ3 antibody (MFI 4000) at
the last follow-up (102 months post-conversion), without any
liver-test abnormalities.
During the follow-up period, among patients receiving mTOR
inhibitors and not having anti-HLA antibodies, two other patients
without DSAs presented with an acute rejection episode (Banff
criteria 5 and 6) at 4 months after the switch. One patient was
receiving sirolimus as a monotherapy (C0 = 10 ng/ml) and the
other was receiving everolimus (C0 = 7 ng/ml), mycophenolate
mofetil (1 g/d), and steroids (5 mg/d). Both patients were suc-
cessfully treated by steroid pulses, and sirolimus was replaced
by tacrolimus for one patient and mycophenolate mofetil was
replaced by tacrolimus for the other.
Before conversion to mTOR inhibitors, the nine remaining
patients had DSAs [anti-HLA class I (n = 1) and anti-class II
antibodies (n = 8)], with a baseline median MFI of 5000 (ranges:
2000–15,000). Three patients had a DSA having a MFI below
3000. After a median follow-up of 25 (range: 6–81) months,
no de novo DSAs were detected, and median MFI was
unchanged. Conversely, in one patient, the DSA, anti-DQ7 (MFI
2000), became undetectable at the last follow-up (67 months)
without any speciﬁc therapy. During the follow-up period, two
of these nine patients presented with an acute rejection episode
(Banff criterion of 6) at 4 and 6 months after the switch. One of
these patients, who had an anti-DQ5 DSA (MFI 15,000), was
receiving everolimus (C0 = 8 ng/ml), mycophenolate sodium
(720 mg/d), and steroids (5 mg/d). The other patient had
anti-DQ3 DSA (MFI 5000), which was treated with sirolimus
(C0 = 7 ng/ml) and steroids (5 mg/d). Both patients were
successfully treated by steroid pulses and mTOR inhibitors were
replaced by tacrolimus. Liver-enzyme levels returned to within
the normal ranges in both cases. In one patient, the anti-DQ5
DSA was not detectable at 5 months after the switch back to
tacrolimus.
mTOR inhibitors were withdrawn in 12 patients (21%) at 6
(range: 3–85) months after conversion because of adverse events.
Hence, overall, after conversion from CNIs to an mTOR inhib-
itor-based CNI-free immunosuppression, three of the 56 patients
developed de novo DSAs (6.5%), a biopsy-proven acute-rejection
episode occurred in four of the 56 patients (7%), and a biopsy-
proven or suspected acute-rejection episode occurred in six of
the 56 patients (10.7%).
In maintenance liver-transplant patients receiving CNIs, we
have previously observed an incidence of DSAs of 9% (17 out of
184 patients) [7]. This rate is similar to the one observed in the
present study, 3 out of 47 patients receiving mTOR-based CNI-
free immunosuppression (6.5%), p = n.s. Kaneku et al., have
observed a similar incidence of DSAs (8.1%) [10]. Although de
novo DSAs occurred more frequently in cyclosporine than
tacrolimus-treated patients, no difference was observed between
CNI and mTOR inhibitor treated patients [10].
In summary, in maintenance LT, the incidence of de novo DSAs
seems to be relatively infrequent and similar between patients
receiving mTOR-based CNI-free immunosuppression and CNI
based immunosuppression, after late conversion to mTOR based
treatment, usually as part of a dual-drug cocktail. Further studies
are required to conﬁrm these data.
Table 1. The patients’ characteristics.
Variable Results 
(n = 56)
Age at transplantation (yr) 51 ± 13
Sex: male/female 46 (82)/10 (18)
Initial liver disease (%)
Alcohol-related liver disease 22 (39.5)
Viral infection 14 (25)
Cancer 13 (23)
Other 7 (12.5)
HLA mismatches
Class I 3.2 ± 0.8
Class II 3.4 ± 0.9
Class I and II 6.6 ± 1.2
Time between liver transplantation and 
conversion to mTOR inhibitors (months) 
[min-max]
34 (1-206)
Cause of mTOR inhibitors use
Cancer 37 (66)
Preserving kidney function 9 (16)
Adverse events from calcineurin inhibitors 4 (7)
Recurrent viral infections 2 (4)
Participation in a clinical trial 4 (7)
Immunosuppressive therapy before mTOR inhibitors were 
introduced (%)
Calcineurin inhibitors 54 (98)
Cyclosporin A 6 (14)
Tacrolimus 48 (84)
Mycophenolic acid 38 (68)
Steroids 53 (98)
Immunosuppressive therapy after the switch (%)
mTOR inhibitors + mycophenolic acid + 
steroids
29 (52)
mTOR inhibitors + mycophenolic acid 8 (14)
mTOR inhibitors + steroids 16 (29)
mTOR inhibitors only 3 (5)
HLA, human leukocyte antigen; mTOR, mammalian target of rapamycin.
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Prophylaxis of bacterial infections in cirrhosis: Is an optimal 25-OH
vitamin D level required?
To the Editor:
We read with interest the position statement based on the EASL
special conference 2013 dealing with ‘‘Bacterial infections in
cirrhosis’’ [1].
Infections in cirrhotic patients are a major problem, both in
terms of the high frequency and also the relative high risk of
associated mortality. Whilst there has already been signiﬁcant
progress, greater knowledge of the pathophysiology and
improvements in the management of these patients are still
crucial. Among the parameters associated with a risk of infection,
those that can be readily addressed during management are of
particular interest. Among them gastrointestinal bleeding, the
severity of the liver insufﬁciency, low protein ascites and a previ-
ous episode of infection are clinical situations that may justify a
primary or a secondary prophylaxis [1]. Randomized control
trials, testing some of these strategies, are in progress (for
example, the interest of norﬂoxacin in the primary prophylaxis
against SBP in patients with ascites, NCT01037959).
We also wish to highlight another recently described risk
factor that should be sought by hepatologists, vitamin D
deﬁciency (<10 ng/ml). We have recently published data that
demonstrate an association between severe deﬁciency in
vitamin D and occurrence of bacterial infection in cirrhotic
patients, independent of the severity of the liver insufﬁciency,
assessed by the Child-Pugh or MELD score [2]. Whilst causality
could not be tested in our prospective observational study,
many other studies have also suggested that vitamin D could
be implicated in the interactions between the host and bacteria.
The anti-bacterial effects of vitamin D may be mediated, but
not only through an increase in the innate immune system
defence [3]. The potential link between infections and vitamin
D deﬁciency has also been recently suggested in patients in
resuscitation units [4].
Vitamin D deﬁciency is frequent in the general population
and has been associated with increased mortality [5]. Prospec-
tive trials of supplementation of vitamin D with calcium in
the elderly reduced osteoporotic fractures and mortality [6].
Cirrhotic patients also frequently exhibit a deﬁciency in vitamin
D and are exposed to osteoporosis [7]. In order to increase
bone health in patients with advanced liver disease, experts
(including the European Association for the Study of the Liver
guidelines for the management of patients suffering from
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